GIÁ TRỊ CỦA ĐỘT BIẾN hTERT C228T TRONG CHẨN ĐOÁN UNG THƯ BIỂU MÔ TẾ BÀO GAN NHIỄM VIRUS VIÊM GAN B

Abstract

Objective: To determine the diagnostic value of the peripheral blood hTERT C228T mutation in Hepatitis B virus (HBV) - associated hepatocellular carcinoma (HCC). Subjects and Methods: The study involved 159 patients with HBV-associated HCC and a control group consisting of 62 patients with HBV-associated cirrhosis and 98 patients with chronic hepatitis B. The peripheral blood hTERT C228T mutation was identified using the Nested-PCR technique combined with real-time PCR. Results: The hTERT C228T mutation in peripheral blood was detected only in the HBV-associated HCC group, with a frequency of 25.2%. It was absent in the HBV-associated cirrhosis and chronic hepatitis B groups (p < 0.001), with a specificity of 100%. Combining the hTERT C228T mutation with plasma AFP in diagnosing HCC yielded superior AUROC values compared to HBV-associated cirrhosis, chronic hepatitis B, and non-cancer groups (AUC values of 0.81, 0.88, and 0.85, respectively), which were higher than when AFP alone was used (AUC values of 0.76, 0.84, and 0.81, respectively). Conclusion: The hTERT C228T mutation has significant diagnostic value in HBV-associated HCC, with high specificity. When combined with AFP levels, it provides greater diagnostic accuracy than AFP levels alone.